Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment

Journal of Infection

Volumn 68, Issue 3, 2014, Pages 252-258

  Hong, Ji Young ^a   Lee, Hye Jon ^a   Kim, Song Yee ^a   Chung, Kyung Soo ^a   Kim, Eun Young ^a   Jung, Ji Ye ^a   Park, Moo Suk ^a   Kim, Young Sam ^a   Kim, Se Kyu ^a   Chang, Joon ^a   Cho, Sang Nae ^a   Kang, Young Ae ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

IP 10; Monitoring; Tuberculosis

Indexed keywords

IP-10; MONITORING; TUBERCULOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; DRUG MONITORING; FEMALE; HUMANS; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 84894071852     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.033     Document Type: Article

References (35)

1. WHO The global tuberculosis report 2012 2012, World Health Organization, Geneva, (WHO/HTM/TB/2012.6).
2. Siddiqi K., Lambert M.L., Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003, 3(5):288-296.
3. Holtz T.H., Sternberg M., Kammerer S., Laserson K.F., Riekstina V., Zarovska E., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144(9):650-659.
4. Wallis R.S., Wang C., Doherty T.M., Onyebujoh P., Vahedi M., Laang H., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010, 10(2):68-69.
5. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360(9332):528-534.
6. Johnson J.L., Hadad D.J., Dietze R., Maciel E.L., Sewali B., Gitta P., et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009, 180(6):558-563.
7. Sharma S.K., Mohan A., Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res 2005, 121(4):550-567.
8. Ferrero E., Biswas P., Vettoretto K., Ferrarini M., Uguccioni M., Piali L., et al. Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cells. Immunology 2003, 108(3):365-374.
9. Ruhwald M., Bodmer T., Maier C., Jepsen M., Haaland M.B., Eugen-Olsen J., et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008, 32(6):1607-1615.
10. Ruhwald M., Bjerregaard-Andersen M., Rabna P., Kofoed K., Eugen-Olsen J., Ravn P. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect 2007, 9(7):806-812.
11. Goletti D., Raja A., Syed Ahamed Kabeer B., Rodrigues C., Sodha A., Carrara S., et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?. PLoS One 2010, 5(9):e12577.
12. Chen Y.C., Chin C.H., Liu S.F., Wu C.C., Tsen C.C., Wang Y.H., et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis Markers 2011, 31(2):101-110.
13. Azzurri A., Sow O.Y., Amedei A., Bah B., Diallo S., Peri G., et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005, 7(1):1-8.
14. Chen D.Y., Shen G.H., Chen Y.M., Chen H.H., Lin C.C., Hsieh C.W., et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int J Tuberc Lung Dis 2011, 15(2):192-200.
15. Kabeer B.S., Raja A., Raman B., Thangaraj S., Leportier M., Ippolito G., et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011, 11:135.
16. Riou C., Perez Peixoto B., Roberts L., Ronacher K., Walzl G., Manca C., et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 2012, 7(5):e36886.
17. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1376-1395.
18. Korean guidelines for tuberculosis 2011, Joint Committee for the Development of Korean Guidelines for Tuberculosis: Korea Centers for Disease Control and Prevention. 1st ed.
19. Hong J.Y., Jung G.S., Kim H., Kim Y.M., Lee H.J., Cho S.N., et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012, 16(12):e855-e859.
20. Lighter-Fisher J., Peng C.H., Tse D.B. Cytokine responses to QuantiFERON(R) peptides, purified protein derivative and recombinant ESAT-6 in children with tuberculosis. Int J Tuberc Lung Dis 2010, 14(12):1548-1555.
21. Aabye M.G., Ruhwald M., Praygod G., Jeremiah K., Faurholt-Jepsen M., Faurholt-Jepsen D., et al. Potential of interferon-gamma-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 2010, 36(6):1488-1490.
22. Belard E., Semb S., Ruhwald M., Werlinrud A.M., Soborg B., Jensen F.K., et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011, 17(11):2340-2349.
23. Vanini V., Petruccioli E., Gioia C., Cuzzi G., Orchi N., Rianda A., et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012, 65(1):49-59.
24. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121(1):308-317.
25. Ng P.C., Li K., Chui K.M., Leung T.F., Wong R.P., Chu W.C., et al. IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants. Pediatr Res 2007, 61(1):93-98.
26. Cannas A., Calvo L., Chiacchio T., Cuzzi G., Vanini V., Lauria F.N., et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 2010, 10:333.
27. Su W.L., Perng W.C., Huang C.H., Yang C.Y., Wu C.P., Chen J.H. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin Vaccine Immunol 2010, 17(2):223-231.
28. Pathan A.A., Wilkinson K.A., Klenerman P., McShane H., Davidson R.N., Pasvol G., et al. Direct exvivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.
29. Carrara S., Vincenti D., Petrosillo N., Amicosante M., Girardi E., Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004, 38(5):754-756.
30. Katiyar S.K., Sampath A., Bihari S., Mamtani M., Kulkarni H. Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12(10):1146-1152.
31. Pai M., Joshi R., Bandyopadhyay M., Narang P., Dogra S., Taksande B., et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 2007, 35(2):98-103.
32. Dominguez J., De Souza-Galvao M., Ruiz-Manzano J., Latorre I., Prat C., Lacoma A., et al. T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis 2009, 63(1):43-51.
33. Kobashi Y., Mouri K., Yagi S., Obase Y., Miyashita N., Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 2009, 58(3):197-204.
34. Denkinger C.M., Pai M., Patel M., Menzies D. Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J Clin Microbiol 2013, 51(2):607-610.
35. Lee S.W., Lee C.T., Yim J.J. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 2010, 10:300.